# Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

> **NCT05732961** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 6 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Myeloproliferative Neoplasm
- Anemia

## Interventions

- **DRUG:** Luspatercept

## Key facts

- **NCT ID:** NCT05732961
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-21
- **Primary completion:** 2026-03-26
- **Final completion:** 2026-09
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05732961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05732961, "Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05732961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*